SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma

NCT07700667 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: SKB500
DRUG: Tislelizumab
DRUG: Cisplatin
DRUG: 5 - FU

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.